On May 28, 2024 NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, reported that it will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) conference in Chicago, May 31–June 4 (booth #31093) (Press release, NeoGenomics Laboratories, MAY 28, 2024, View Source [SID1234643757]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"With cancer cases on the rise, we’ve seen tremendous growth in FDA-approved targeted therapies and immunotherapies, making proper test selection critical for precision medicine-based patient management," said Chris Smith, CEO of NeoGenomics. "Our wide breadth of testing solutions represents a significant milestone in our mission to empower clinicians with the tools needed to deliver the best possible care to patients, whether it’s early or advanced stage, and whether there is tissue or not."
Recognizing the benefits of concurrent testing, as supported by the National Comprehensive Cancer Network (NCCN) guidelines, NeoGenomics’ comprehensive lung offering allows for complementary tissue and liquid biopsy testing. The test portfolio provides a comprehensive approach to diagnosis, therapy selection, prognosis, and clinical trial options tailored to each patient’s unique needs, addressing the disease’s complexities:
Early Stage NSCLC is the industry’s first therapy selection panel for early-stage non-small cell lung cancer (NSCLC), delivering actionable insights within seven days.
DNA & RNA Lung is a 50-gene NGS panel enriched with MSI and TMB analysis to facilitate precise therapy selection and clinical trial matching.
InvisionFirst Lung is a liquid biopsy assay that detects 37 genes crucial to NSCLC treatment. It surpasses tissue-based assays in actionable alterations and is available for patients without viable tissue samples.
Comprehensive Solid Tumor test analyzes 517 genes via DNA and RNA next-generation sequencing, providing clinicians with a complementary understanding of the patient’s cancer profile to guide optimal treatment options.
NeoGenomics will also feature COMPASS, a suite of single-order sample-to-diagnosis services for hematological malignancies. With over 100 subtypes of leukemias, lymphomas, and myelomas, reaching a definitive diagnosis requires the time and expertise to manage ever-evolving clinical guidelines and testing criteria. COMPASS provides an all-in-one assessment with actionable diagnostic and prognostic information unique to the patient.
In addition to highlighting these solutions, NeoGenomics will present a poster, titled "Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples," during the Quality Care/Health Services Research poster session on June 3, 2024 (Abstract #11185; Poster Board #380).